Investing.com - Arcadia Biosciences reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Arcadia Biosciences announced earnings per share of $-0.120 on revenue of $1.88M. Analysts polled by Investing.com anticipated EPS of $-0.230 on revenue of $2M.
Arcadia Biosciences shares are down 28.35% from the beginning of the year and are trading at $0.310 , down-from-52-week-high.
Arcadia Biosciences shares lost 5.20% in after-hours trade following the report.
Arcadia Biosciences follows other major Consumer Staples sector earnings this month
Arcadia Biosciences's report follows an earnings beat by Procter&Gamble on Wednesday, October 19, 2022, who reported EPS of $1.57 on revenue of $20.61B, compared to forecasts EPS of $1.56 on revenue of $20.37B.
Coca-Cola had beat expectations on Tuesday, October 25, 2022 with third quarter EPS of $0.69 on revenue of $11.06B, compared to forecast for EPS of $0.6388 on revenue of $10.53B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar